Provided by Tiger Trade Technology Pte. Ltd.

Citius Pharmaceuticals, Inc.

0.6910
-0.0261-3.64%
Post-market: 0.69100.00000.00%16:10 EST
Volume:378.81K
Turnover:262.20K
Market Cap:15.46M
PE:-0.24
High:0.7200
Open:0.7100
Low:0.6810
Close:0.7171
52wk High:2.97
52wk Low:0.6300
Shares:22.38M
Float Shares:18.81M
Volume Ratio:0.50
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9159
EPS(LYR):-5.9739
ROE:-47.85%
ROA:-17.68%
PB:0.19
PE(LYR):-0.12

Loading ...

Company Profile

Company Name:
Citius Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
23
Office Location:
11 Commerce Drive,First Floor,Cranford,New Jersey,United States
Zip Code:
07016
Fax:
- -
Introduction:
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Directors

Name
Position
Leonard Mazur
Chief Executive Officer, Chairman, Secretary and Director
Myron Holubiak
Director and Executive Vice-Chairman
Carol Webb
Director
Dennis M. McGrath
Director
Eugene Holuka
Director
Robert Smith
Director
Suren Dutia
Director

Shareholders

Name
Position
Leonard Mazur
Chief Executive Officer, Chairman, Secretary and Director
Jaime Bartushak
Chief Business Officer and Chief Financial Officer
Myron S. Czuczman
Chief Medical Officer and Executive Vice President